Related Experiment Video
Updated: Aug 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cardiomyopathy, familial dilated
Matthew R G Taylor1, Elisa Carniel, Luisa Mestroni
1University of Colorado Cardiovascular Institute and Adult Medical Genetics Program, Department of Internal Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA. Matthew.Taylor@UCHSC.edu
Insights
Familial dilated cardiomyopathy (FDC) is an inherited heart muscle disease often caused by genetic mutations. Early identification through family screening and genetic testing enables timely interventions to manage heart failure and improve outcomes.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Dilated cardiomyopathy (DCM) is a significant heart muscle disease marked by enlarged ventricles and reduced pumping function.
- Familial DCM (FDC), accounting for 20-48% of DCM cases, stems from genetic mutations affecting cardiac myocyte proteins.
- DCM presents risks of heart failure, arrhythmias, and premature death, with a prevalence of 1 in 2500.
Purpose of the Study:
- To highlight the importance of family history analysis and genetic testing in identifying FDC.
- To emphasize the benefits of early diagnosis for timely intervention and disease management.
- To outline current management strategies for FDC, focusing on heart failure and arrhythmia control.
Main Methods:
- Utilizing family history analysis and pedigree evaluation to identify at-risk families.
- Employing clinical genetic testing for known FDC-associated genes.
- Applying standard criteria for FDC family evaluation and screening.
Main Results:
- Early or presymptomatic identification of FDC patients is achievable through screening.
- Genetic counseling aids in identifying at-risk asymptomatic family members for regular monitoring.
- Screening facilitates earlier lifestyle modifications and pharmacological therapy initiation.
Conclusions:
- Family screening and genetic testing are crucial for early FDC detection and management.
- Proactive management, including lifestyle changes and pharmacotherapy, can mitigate disease progression.
- Advanced therapies and heart transplantation remain options for severe FDC cases.
Abstract:
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is termed familial DCM (FDC). FDC may account for 20-48% of DCM. FDC is principally caused by genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac myocyte. Family history analysis is an important tool for identifying families affected by FDC. Standard criteria for evaluating FDC families have been published and the use of such criteria is increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of their disease. This presents an opportunity to invoke lifestyle changes and to provide pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify additional asymptomatic family members who are at risk of developing symptoms, allowing for regular screening of these individuals. The management of FDC focuses on limiting the progression of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension, limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy. Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices have progressively expanding usage. Patients with severe heart failure, severe reduction of the functional capacity and depressed left ventricular ejection fraction have a low survival rate and may require heart transplant.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

